Conditions: Primary Sclerosing Cholangitis (PSC)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.

Detailed description:

Arms:
arm 1: LUM001 administered orally once each day

Interventions: intervention 1: LUM001
Intervention descriptions: intervention 1: LUM001 oral dose

Protocol document: